- Home
- EPRT vs MDGL Comparison
EPRT vs MDGL Comparison
Compare EPRT & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRT
- MDGL
- Stock Information
- Founded
- EPRT 2016
- MDGL 2011
- Country
- EPRT United States
- MDGL United States
- Employees
- EPRT N/A
- MDGL N/A
- Industry
- EPRT Real Estate Investment Trusts
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- EPRT Real Estate
- MDGL Health Care
- Exchange
- EPRT Nasdaq
- MDGL Nasdaq
- Market Cap
- EPRT 6.0B
- MDGL 6.8B
- IPO Year
- EPRT 2018
- MDGL N/A
- Fundamental
- Price
- EPRT $32.16
- MDGL $294.64
- Analyst Decision
- EPRT Buy
- MDGL Strong Buy
- Analyst Count
- EPRT 14
- MDGL 10
- Target Price
- EPRT $34.84
- MDGL $420.63
- AVG Volume (30 Days)
- EPRT 1.5M
- MDGL 373.7K
- Earning Date
- EPRT 04-23-2025
- MDGL 05-01-2025
- Dividend Yield
- EPRT 3.67%
- MDGL N/A
- EPS Growth
- EPRT N/A
- MDGL N/A
- EPS
- EPRT 1.16
- MDGL N/A
- Revenue
- EPRT $475,463,000.00
- MDGL $317,383,000.00
- Revenue This Year
- EPRT $19.43
- MDGL $230.69
- Revenue Next Year
- EPRT $17.18
- MDGL $74.76
- P/E Ratio
- EPRT $27.71
- MDGL N/A
- Revenue Growth
- EPRT 25.32
- MDGL N/A
- 52 Week Low
- EPRT $26.07
- MDGL $200.08
- 52 Week High
- EPRT $34.88
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- EPRT 54.98
- MDGL 39.29
- Support Level
- EPRT $31.52
- MDGL $287.46
- Resistance Level
- EPRT $32.35
- MDGL $349.00
- Average True Range (ATR)
- EPRT 0.62
- MDGL 17.20
- MACD
- EPRT 0.03
- MDGL -2.36
- Stochastic Oscillator
- EPRT 65.77
- MDGL 11.67
About EPRT Essential Properties Realty Trust Inc.
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.